Skiplink Navigation

Main Features

Novartis opens large flu vaccine plant in US

Swiss pharmaceutical group Novartis has inaugurated its first large-scale flu cell culture and adjuvant manufacturing plant in the United States.

The facility, with a cost of almost $1 billion (SFr999 million), is a partnership between the Basel-based company and the US Department of Health and Human Services.

Adjuvants are additives that boost the body's response to a vaccine and lowers the dose needed. They are not licensed in the US at present because of widespread public suspicion of new vaccine ingredients.

Novartis explained in a statement that the plant in Holly Springs, North Carolina, was the first of its kind in the US and was a "milestone" in efforts to improve influenza vaccine manufacturing technology in the US and enhance domestic pandemic preparedness.

The facility will use modern biotechnologies for flu vaccine production to replace the 50-year-old egg process.

It is designed to supply 150 million doses of pandemic vaccine within six months of a pandemic declaration and could respond from 2011. and agencies


Neuer Inhalt

Horizontal Line

subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.

Click here to see more newsletters

WEF 2018

WEF Teaser 2018